Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Liabilities (2016 - 2026)

OptimizeRx's Total Liabilities history spans 16 years, with the latest figure at $48.6 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 10.24% to $48.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.6 million, a 10.24% decrease, with the full-year FY2025 number at $48.6 million, down 10.24% from a year prior.
  • Total Liabilities hit $48.6 million in Q4 2025 for OptimizeRx, up from $48.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for OPRX hit a ceiling of $56.8 million in Q4 2023 and a floor of $5.5 million in Q2 2023.
  • Historically, Total Liabilities has averaged $27.3 million across 5 years, with a median of $9.1 million in 2021.
  • Biggest five-year swings in Total Liabilities: crashed 54.52% in 2021 and later skyrocketed 841.25% in 2024.
  • Tracing OPRX's Total Liabilities over 5 years: stood at $9.6 million in 2021, then fell by 11.09% to $8.5 million in 2022, then soared by 565.32% to $56.8 million in 2023, then decreased by 4.67% to $54.2 million in 2024, then dropped by 10.24% to $48.6 million in 2025.
  • Business Quant data shows Total Liabilities for OPRX at $48.6 million in Q4 2025, $48.1 million in Q3 2025, and $50.0 million in Q2 2025.